Host defense protein (hdp) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract

Abstract

The present invention provides methods for treating and/or preventing inflammatory diseases of the gastrointestinal tract with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, and the use of compositions comprising the same.

We claim: 
     
         1 . A method of treatment of inflammatory diseases of the gastrointestinal tract selected from the group consisting of collagenous colitis, lymphocytic colitis, Crohn's disease, and irritable bowel syndrome, in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of brilacidin or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method according to  claim 1 , wherein brilacidin or a pharmaceutically acceptable salt thereof is administered together with an antibiotic. 
     
     
         3 . The method according to  claim 1 , wherein said compound is administered orally. 
     
     
         4 . The method according to  claim 1 , wherein said compound is administered at a daily dose of 0.01 to 70 milligrams per kilogram of body weight of the patient. 
     
     
         5 . A method according to  claim 1 , wherein said compound is administered at a daily dose of 0.5 to 20 milligrams per kilogram of body weight of the patient. 
     
     
         6 . The method as claimed in  claim 1 , wherein said therapeutically effective amount of brilacidin is a dose of between 50 mg to 200 mg per day. 
     
     
         7 . The method according to  claim 1 , wherein brilacidin or a pharmaceutically acceptable salt thereof is administered in a rectal enema. 
     
     
         8 . The method according to  claim 1 , wherein the patient is suffering from Crohn's disease. 
     
     
         9 . The method according to  claim 8 , wherein brilacidin or a pharmaceutically acceptable salt thereof is administered together with an antibiotic. 
     
     
         10 . The method according to  claim 8 , wherein said compound is administered orally. 
     
     
         11 . The method according to  claim 8 , wherein said compound is administered at a daily dose of 0.01 to 70 milligrams per kilogram of body weight of the patient. 
     
     
         12 . The method according to  claim 8 , wherein said compound is administered at a daily dose of 0.5 to 20 milligrams per kilogram of body weight of the patient. 
     
     
         13 . The method as claimed in  claim 8 , wherein said therapeutically effective amount of brilacidin is a dose of between 50 mg to 200 mg per day. 
     
     
         14 . The method according to  claim 8 , wherein brilacidin or a pharmaceutically acceptable salt thereof is administered in a rectal enema.